- Home
- NDMO vs KROS Comparison
NDMO vs KROS Comparison
Compare NDMO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- KROS
- Stock Information
- Founded
- NDMO 2019
- KROS 2015
- Country
- NDMO United States
- KROS United States
- Employees
- NDMO N/A
- KROS N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- NDMO Finance
- KROS Health Care
- Exchange
- NDMO Nasdaq
- KROS Nasdaq
- Market Cap
- NDMO 620.6M
- KROS 565.0M
- IPO Year
- NDMO N/A
- KROS 2020
- Fundamental
- Price
- NDMO $10.39
- KROS $15.66
- Analyst Decision
- NDMO
- KROS Buy
- Analyst Count
- NDMO 0
- KROS 14
- Target Price
- NDMO N/A
- KROS $20.56
- AVG Volume (30 Days)
- NDMO 218.6K
- KROS 430.7K
- Earning Date
- NDMO 01-01-0001
- KROS 11-05-2025
- Dividend Yield
- NDMO 6.75%
- KROS N/A
- EPS Growth
- NDMO N/A
- KROS N/A
- EPS
- NDMO N/A
- KROS 0.47
- Revenue
- NDMO N/A
- KROS $232,844,000.00
- Revenue This Year
- NDMO N/A
- KROS $5,579.44
- Revenue Next Year
- NDMO N/A
- KROS N/A
- P/E Ratio
- NDMO N/A
- KROS $33.65
- Revenue Growth
- NDMO N/A
- KROS 85820.30
- 52 Week Low
- NDMO $8.99
- KROS $9.12
- 52 Week High
- NDMO $11.24
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- NDMO 72.17
- KROS 59.38
- Support Level
- NDMO $9.72
- KROS $15.23
- Resistance Level
- NDMO $9.98
- KROS $15.85
- Average True Range (ATR)
- NDMO 0.11
- KROS 0.52
- MACD
- NDMO 0.07
- KROS 0.01
- Stochastic Oscillator
- NDMO 88.55
- KROS 72.91
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.